18 Poster Presentations on Investigational and Existing
Products
LAVAL, Quebec, Oct. 15, 2019 /CNW/ -- Bausch Health Companies
Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho
Dermatologics, one of the largest prescription dermatology health
care businesses, today announced the presentation of 18 posters
during the Fall Clinical Dermatology Conference in Las Vegas (Oct. 17-20,
2019). The presentations will feature analyses on ALTRENO®
(tretinoin 0.05%) Lotion, BRYHALI® (halobetasol propionate 0.01%)
Lotion, DUOBRII® (halobetasol propionate 0.01% and tazarotene
0.045%) Lotion and SILIQ® (brodalumab) injection, as well as a new
data on the investigational drug IDP-123 (tazarotene 0.045%)
Lotion. Please see below for warning about suicidal ideation and
behavior with SILIQ.
"At this year's Fall Clinical, new data will be presented across
our psoriasis and acne portfolios, which have expanded
significantly over the last year with the FDA approvals of DUOBRII,
BRYHALI and ALTRENO," said Bill
Humphries, president, Ortho Dermatologics. "A total of 18
posters will be presented during the meeting. This includes data on
our investigational acne treatment IDP-123, which is currently
under review by the FDA with a PDUFA date of Dec. 22, 2019, as well as analyses that further
demonstrate the clinical benefits of our current portfolio. Doing
so allows us to help address the unmet needs of patients and
educate physicians with new information that can help inform their
treatment decisions."
The complete list of all poster presentations that will include
Ortho Dermatologics products and pipeline programs during the
meeting is as follows.
ALTRENO® (tretinoin) Lotion, 0.05%
- Bhatia et al. "A Randomized, Observer-blind, Split-face
Study to Assess Compatibility of Facial Foundation Makeup with
Tretinoin 0.05% Lotion and Skin Texture After Application"
- Han et al. "Novel Tretinoin 0.05% Lotion for the Once-Daily
Treatment of Moderate-to-Severe Acne Vulgaris in an Asian
Population"
- St. Surin-Lord et al. "Acne-Related Quality of Life:
Efficacy of a Novel Tretinoin 0.05% Lotion in Male and Female
Patients with Moderate-to-Severe Disease"
- Woolery-Lloyd et al. "Acne-Related Quality of Life:
Correlation Between Acne Symptom Scores and Other Domains Following
Treatment with Tretinoin 0.05% Lotion"
BRYHALI® (halobetasol propionate) Lotion,
0.01%
- Bhatia et al. "Halobetasol 0.01% Lotion in the Treatment of
Moderate-to-Severe Plaque Psoriasis of the Lower
Extremities"
DUOBRII® (halobetasol propionate 0.01% and tazarotene
0.045%) Lotion
- Alexis et al. "Efficacy, Safety, and Tolerability of a
Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the
Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic
Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled
Trials"
- Glick et al. "Efficacy of Halobetasol 0.01%/Tazarotene
0.045% (HP/TAZ) Fixed Combination in the Treatment of Moderate
Plaque Psoriasis: Indirect Comparison Between Pooled Phase 3 Trials
of HP/TAZ and Oral Treatment (Apremilast)"
- Gold et al. "Long-Term Management of Moderate-to-Severe
Plaque Psoriasis: Maintenance of Treatment Success Following
Cessation of Fixed Combination Halobetasol Propionate 0.01% And
Tazarotene 0.045% (HP/TAZ) Lotion"
- Lebwohl et al. "Efficacy, Safety, and Tolerabilty of a
Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the
Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two
Phase 3 Randomized Controlled Trials"
- Tanghetti et al. "Optimized Formulation for Topical
Application of a Fixed Combination Halobetasol/Tazarotene Lotion
Using Polymeric Emulsion Technology."
SILIQ® (brodalumab) Injection
- Armstrong et al.
"Importance of Complete Skin Clearance on Quality of Life:
Analysis of Three Phase 3 Studies"
- Bhatia et al. "Maintenance and Improvement of Skin Clearance
Response With Brodalumab Among Patients With Moderate-to-Severe
Psoriasis"
- Gottlieb et al. "Long-term Efficacy and Safety of Brodalumab
in Patients With or Without History of Psoriatic Arthritis:
Analysis of Two Phase 3 Psoriasis Studies"
- Lebwohl et al. "Long-term Efficacy and Safety of Brodalumab
in Patients With Psoriasis Who Did Not Respond to Prior
Biologics"
- Leonardi et al. "Long-term Efficacy and Safety of Brodalumab
Through 120 Weeks and After Withdrawal and Retreatment"
- Ehst et al. "Long-term Efficacy and Safety of
Brodalumab in Patients With Psoriasis Disease Duration ≥10 Years:
Analysis of Two Phase 3 Studies"
- Prussick et al. "Patients With Psoriasis Treated With
Brodalumab: A Pooled Post Hoc Analysis of a Marker of Liver
Inflammation in Individuals With Potential Indicators of Early
Nonalcoholic Fatty Liver Disease"
IDP-123 (tazarotene 0.045%) Lotion
- Draelos et al. "Comparison of a novel tazarotene 0.045%
lotion to tazarotene 0.1% cream: patient-reported outcomes from a
phase 2 clinical trial"
About Ortho Dermatologics
Ortho Dermatologics is one
of the largest prescription dermatology businesses dedicated to
helping patients in the treatment of a range of therapeutic areas,
including psoriasis, actinic keratosis, acne, atopic dermatitis and
other dermatoses. The Ortho Dermatologics portfolio includes
several leading acne, anti-fungal and corticosteroid-responsive
dermatoses products. More information can be found at
www.ortho-dermatologics.com.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.bauschhealth.com.
What is the most important information I should know about
SILIQ?
Suicidal thoughts or behavior: Some patients taking SILIQ
have had suicidal thoughts or ended their own lives. This risk is
higher if you have a history of suicidal thoughts or depression. It
is not known if SILIQ causes these thoughts or actions. Get medical
help right away if you or a family member notices that you have any
of the following symptoms: new or worsening depression, anxiety, or
mood problems; thoughts of suicide, dying, or hurting yourself;
attempt to commit suicide, or acting on dangerous impulses; other
unusual changes in your behavior or mood.
Your healthcare provider will give you a SILIQ patient/wallet
card about symptoms that need medical attention right away. Carry
the card with you during treatment with SILIQ and show it to all of
your healthcare providers.
Please click here for full Prescribing Information for SILIQ,
including Boxed Warning about suicidal ideation and behavior, and
Medication Guide.
Please see full Prescribing Information for DUOBRII, BRYHALI and
ALTRENO.
Forward-looking Statements
This news release may
contain forward-looking statements, which may generally be
identified by the use of the words "anticipates," "expects,"
"intends," "plans," "should," "could," "would," "may," "will,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks and uncertainties discussed in the Company's most
recent annual or quarterly report and detailed from time to time in
the Company's other filings with the Securities and Exchange
Commission and the Canadian Securities Administrators, which
factors are incorporated herein by reference. In addition, certain
material factors and assumptions have been applied in making these
forward-looking statements, including that the risks and
uncertainties outlined above will not cause actual results or
events to differ materially from those described in these
forward-looking statements. The Company believes that the material
factors and assumptions reflected in these forward-looking
statements are reasonable, but readers are cautioned not to place
undue reliance on any of these forward-looking statements. These
forward-looking statements speak only as of the date hereof. Bausch
Health undertakes no obligation to update any of these
forward-looking statements to reflect events or circumstances after
the date of this news release or to reflect actual outcomes, unless
required by law.
ALTRENO, BRYHALI, DUOBRII and SILIQ are trademarks of Ortho
Dermatologics' affiliated entities.
© 2019 Ortho Dermatologics' affiliated
entities.
MTB.0444.USA.19
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
(908)
927-1198
|
(877) 281-6642 (toll
free)
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bausch-healths-ortho-dermatologics-business-to-present-data-at-the-fall-clinical-dermatology-conference-300938471.html
SOURCE Bausch Health Companies Inc.